You have full text access to this OnlineOpen article

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

  1. J. ZENG1,
  2. Y.-Q. LI1,
  3. X.-L. ZUO1,
  4. Y.-B. ZHEN1,
  5. J. YANG1,
  6. C.-H. LIU2

Article first published online: 30 JUL 2008

DOI: 10.1111/j.1365-2036.2008.03818.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 28, Issue 8, pages 994–1002, October 2008

Additional Information

How to Cite

ZENG, J., LI, Y.-Q., ZUO, X.-L., ZHEN, Y.-B., YANG, J. and LIU, C.-H. (2008), Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 28: 994–1002. doi: 10.1111/j.1365-2036.2008.03818.x

Author Information

  1. 1

    Department of Gastroenterology, Qilu Hospital

  2. 2

    Center of Medical Molecular Biology, Shandong University School of Medicine, Jinan, Shandong Province, China

*Prof. Y.-Q. Li, Department of Gastroenterology, Qilu Hospital, Shandong University, No. 107, Wenhua Xi Road, Jinan, Shandong Province 250012, China. E-mail: liyanqing@sdu.edu.cn

Publication History

  1. Issue published online: 20 SEP 2008
  2. Article first published online: 30 JUL 2008
  3. Publication data Submitted 10 March 2008 First decision 26 March 2008 Resubmitted 24 June 2008 Resubmitted 24 July 2008 Accepted 25 July 2008 Epub Accepted Article 30 July 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (220K)

Summary

Background  The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS).

Aim  To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.

Methods  Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.

Results  Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics treatment, small bowel permeability decreased significantly from 0.038 (0.024) at baseline to 0.023 (0.020) (P = 0.004), the proportion of patients with increased small bowel permeability was lower than baseline (28.6% vs. 64.3%, P = 0.023). However, colonic permeability improved neither in the probiotics group nor in the placebo group at week 4. Treatment with probiotics significantly decreased the mean global IBS scores compared with the baseline scores (9.62 ± 1.05 vs. 7.64 ± 1.24, P < 0.001).

Conclusion  Short-term active lactic acid bacteria treatment for D-IBS improved mucosal barrier function.

View Full Article (HTML) Get PDF (220K)